Literature DB >> 18794080

Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway.

Vitaly Margulis1, Tapati Maity, Xiu-Ying Zhang, Simon J Cooper, John A Copland, Christopher G Wood.   

Abstract

PURPOSE: Alterations in transforming growth factor-beta (TGF-beta) signaling occur early during malignant transformation of renal epithelial cells and are associated with loss of type III TGF-beta receptor (TbetaRIII) expression. We evaluated the role of TbetaRIII in mediation of apoptosis using in vitro cell culture and in vivo animal models of clear cell renal cell carcinoma. EXPERIMENTAL
DESIGN: TbetaR3 expression was manipulated with adenoviral gene vector delivery system in vitro and in vivo. Induction of apoptosis and signaling through the Smad and mitogen-activated protein kinase (MAPK) pathways were examined at various time points after infection. To study viral oncolysis in vivo, human renal cell carcinoma cells were implanted s.c. in the flanks of nude mice and treated with intratumoral injections of adenovirus.
RESULTS: Restoring TbetaRIII expression in clear cell renal cell carcinoma resulted in a marked induction of apoptosis using in vitro cell culture and in vivo animal models. The expression of the cytoplasmic domain, but not the extracellular domain, of TbetaRIII mimicked the induction of apoptosis by full-length TbetaRIII in cell culture and the growth inhibition of tumors in athymic nude mice. TbetaRIII-associated apoptosis was not dependent on signaling through the canonical TGF-beta/Smad pathway but was mediated through p38 MAPK.
CONCLUSION: These findings indicate a novel mechanistic antitumor function for TbetaRIII and further support its role as an important tumor suppressor in clear cell renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794080      PMCID: PMC2844539          DOI: 10.1158/1078-0432.CCR-08-0546

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

Review 1.  p38 MAP kinase's emerging role as a tumor suppressor.

Authors:  Dmitry V Bulavin; Albert J Fornace
Journal:  Adv Cancer Res       Date:  2004       Impact factor: 6.242

2.  A subtle change in p38 MAPK activity is sufficient to suppress in vivo tumorigenesis.

Authors:  Oleg Timofeev; Ting Yi Lee; Dmitry V Bulavin
Journal:  Cell Cycle       Date:  2005-01-30       Impact factor: 4.534

3.  Expression cloning and characterization of the TGF-beta type III receptor.

Authors:  X F Wang; H Y Lin; E Ng-Eaton; J Downward; H F Lodish; R A Weinberg
Journal:  Cell       Date:  1991-11-15       Impact factor: 41.582

4.  Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system.

Authors:  F López-Casillas; S Cheifetz; J Doody; J L Andres; W S Lane; J Massagué
Journal:  Cell       Date:  1991-11-15       Impact factor: 41.582

Review 5.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

6.  Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Authors:  S Dennler; S Itoh; D Vivien; P ten Dijke; S Huet; J M Gauthier
Journal:  EMBO J       Date:  1998-06-01       Impact factor: 11.598

7.  Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart.

Authors:  C B Brown; A S Boyer; R B Runyan; J V Barnett
Journal:  Science       Date:  1999-03-26       Impact factor: 47.728

8.  Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.

Authors:  J N Lavoie; G L'Allemain; A Brunet; R Müller; J Pouysségur
Journal:  J Biol Chem       Date:  1996-08-23       Impact factor: 5.157

9.  MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation.

Authors:  Isaac A Manke; Anhco Nguyen; Daniel Lim; Mary Q Stewart; Andrew E H Elia; Michael B Yaffe
Journal:  Mol Cell       Date:  2005-01-07       Impact factor: 17.970

10.  Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites.

Authors:  F López-Casillas; H M Payne; J L Andres; J Massagué
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539

View more
  11 in total

Review 1.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

2.  Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Authors:  S J Cooper; H Zou; S N Legrand; L A Marlow; C A von Roemeling; D C Radisky; K J Wu; N Hempel; V Margulis; H W Tun; G C Blobe; C G Wood; J A Copland
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

3.  Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Authors:  Catherine E Gatza; Alisha Holtzhausen; Kellye C Kirkbride; Allyson Morton; Michael L Gatza; Michael B Datto; Gerard C Blobe
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

Review 4.  Roles for the type III TGF-beta receptor in human cancer.

Authors:  Catherine E Gatza; Sun Young Oh; Gerard C Blobe
Journal:  Cell Signal       Date:  2010-02-12       Impact factor: 4.315

5.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15

6.  Adenovirus E1A and E1B-19K proteins protect human hepatoma cells from transforming growth factor beta1-induced apoptosis.

Authors:  Vera L Tarakanova; William S M Wold
Journal:  Virus Res       Date:  2009-10-23       Impact factor: 3.303

7.  Downregulation of TGF-beta receptor types II and III in oral squamous cell carcinoma and oral carcinoma-associated fibroblasts.

Authors:  Wenxia Meng; Qingjie Xia; Lanyan Wu; Sixiu Chen; Xin He; Lin Zhang; Qinghong Gao; Hongmei Zhou
Journal:  BMC Cancer       Date:  2011-02-28       Impact factor: 4.430

8.  The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells.

Authors:  Kathleen E Lambert; Huang Huang; Karthikeyan Mythreye; Gerard C Blobe
Journal:  Mol Biol Cell       Date:  2011-03-16       Impact factor: 4.138

9.  Betaglycan (TβRIII) is expressed in the thymus and regulates T cell development by protecting thymocytes from apoptosis.

Authors:  German R Aleman-Muench; Valentin Mendoza; Kaye Stenvers; Eduardo A Garcia-Zepeda; Fernando Lopez-Casillas; Chander Raman; Gloria Soldevila
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

10.  Role of TGF-β receptor III localization in polarity and breast cancer progression.

Authors:  Alison E Meyer; Catherine E Gatza; Tam How; Mark Starr; Andrew B Nixon; Gerard C Blobe
Journal:  Mol Biol Cell       Date:  2014-05-28       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.